News from Xellia

Today, Xellia Pharmaceuticals announces the expansion plans of its manufacturing capabilities in Hungary. This is consistent with Xellia’s long-term strategy to continue its European production of anti-infective medicines the world depends on, despite operating in a fierce competitive landscape with intense price pressure and rising operational expenses.

It was a Friday evening in the Emirates. The working week was over. Businesses had closed their doors. People were heading home for the weekend. Then the phone rang.

We launched a new website and refreshed visual identity for Xellia. This is more than just a new design. It is a reflection of who we are today - a global company with proud European roots and an enduring role in helping save lives through critical active pharmaceutical ingredients (APIs).

The company’s Copenhagen manufacturing site will undergo a gradual, multi-phased closure over the next eight to 10 years. The company does not expect any employment impact on its Copenhagen manufacturing site for the next three to four years as part of this decision.

Xellia Pharmaceuticals ('Xellia') is pleased to announce that it has completed the divestment of its US-based institutional activities to Hikma Pharmaceuticals (Hikma), a leading global supplier of generic injectables, following clearance under applicable US antitrust laws. 

Xellia Pharmaceuticals ('Xellia'), a global leader in specialty anti-infective treatments and critical care therapies, is pleased to announce the divestment of its US-based institutional activities to Hikma Pharmaceuticals (Hikma), a leading global supplier of generic injectables.

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer.